Gregory M. Asnis

8.2k total citations · 1 hit paper
136 papers, 6.2k citations indexed

About

Gregory M. Asnis is a scholar working on Psychiatry and Mental health, Pharmacology and Behavioral Neuroscience. According to data from OpenAlex, Gregory M. Asnis has authored 136 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Psychiatry and Mental health, 34 papers in Pharmacology and 32 papers in Behavioral Neuroscience. Recurrent topics in Gregory M. Asnis's work include Treatment of Major Depression (33 papers), Stress Responses and Cortisol (32 papers) and Tryptophan and brain disorders (28 papers). Gregory M. Asnis is often cited by papers focused on Treatment of Major Depression (33 papers), Stress Responses and Cortisol (32 papers) and Tryptophan and brain disorders (28 papers). Gregory M. Asnis collaborates with scholars based in United States, Japan and Austria. Gregory M. Asnis's co-authors include H. M. van Praag, Scott Wetzler, Uriel Halbreich, William C. Sanderson, Richard De La Garza, Jill Harkavy‐Friedman, Margaret L Kaplan, Edward J. Sachar, René S. Kahn and Barbara O. Rothbaum and has published in prestigious journals such as JAMA, American Journal of Psychiatry and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Gregory M. Asnis

129 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Sertraline Treatment of Posttraumatic Stress Disorder

2000 502 citations Gregory M. Asnis, Barbara O. Rothbaum et al. profile →

Peers

Countries citing papers authored by Gregory M. Asnis

Since Specialization

Citations

This map shows the geographic impact of Gregory M. Asnis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory M. Asnis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory M. Asnis more than expected).

Fields of papers citing papers by Gregory M. Asnis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory M. Asnis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory M. Asnis. The network helps show where Gregory M. Asnis may publish in the future.

Co-authorship network of co-authors of Gregory M. Asnis

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory M. Asnis. A scholar is included among the top collaborators of Gregory M. Asnis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory M. Asnis. Gregory M. Asnis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Levomilnacipran for the treatment of major depressive disorder: a review 2015 ·Neuropsychiatric Disease and Treatment ·Gregory M. Asnis, Margaret Henderson	20
2	Zolpidem Extended-Release Improves Sleep and Next-Day Symptoms in Comorbid Insomnia and Generalized Anxiety Disorder 2009 ·Journal of Clinical Psychopharmacology ·Maurizio Fava, Gregory M. Asnis, Ram Shrivastava, Bruce Lydiard, Bijan Bastani, David V. Sheehan, Thomas Roth	52
3	Paroxetine for prevention of depressive symptoms induced by interferon‐alpha and ribavirin for hepatitis C 2007 ·Alimentary Pharmacology & Therapeutics ·Charles L. Raison, Bobbi J. Woolwine, (unknown), Andrey Borisov, (unknown), Jeffrey P. Staab, John Zajecka, (unknown), Max Henderson, John F. Reinus, Dwight L. Evans, Gregory M. Asnis, Andrew H. Miller	114
4	Sleep Disturbances in Patients with Post-Traumatic Stress Disorder 2006 ·CNS Drugs ·Michael J. Maher, Simon A. Rego, Gregory M. Asnis	256
5	Interferon-Induced Depression in Chronic Hepatitis C: A Review of Its Prevalence, Risk Factors, Biology, and Treatment Approaches 2006 ·Journal of Clinical Gastroenterology ·Gregory M. Asnis, Richard De La Garza	136
6	Venlafaxine Extended Release in Posttraumatic Stress Disorder 2006 ·Journal of Clinical Psychopharmacology ·Jonathan Davidson, Barbara O. Rothbaum, Phebe Tucker, Gregory M. Asnis, I. Benattia, Jeff Musgnung	105
7	A Randomized Controlled Trial of Venlafaxine Extended Release in Generalized Social Anxiety Disorder 2005 ·The Journal of Clinical Psychiatry ·Michael R. Liebowitz, Richard M. Mangano, Jacques Bradwejn, Gregory M. Asnis	78
8	Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients 2001 ·Psychiatry Research ·Gregory M. Asnis, Faiq A. Hameedi, Andrew W. Goddard, Steven G. Potkin, Donald W. Black, (unknown), (unknown), Scott W. Woods	53
9	Asking Adolescents to Explain Discrepancies in Self‐Reported Suicidality 1998 ·Suicide and Life-Threatening Behavior ·Drew M. Velting, Jill H. Rathus, Gregory M. Asnis	29
10	VIOLENCE AND HOMICIDAL BEHAVIORS IN PSYCHIATRIC DISORDERS 1997 ·Psychiatric Clinics of North America ·Gregory M. Asnis, Margaret L Kaplan, (unknown), (unknown)	73
11	Panic disorder : clinical, biological, and treatment aspects 1995 ·Wiley eBooks ·Gregory M. Asnis, H. M. van Praag	22
12	Functional interrelationship of serotonin and norepinephrine: Cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects 1992 ·Psychiatry Research ·Gregory M. Asnis, Scott Wetzler, William C. Sanderson, RenéS. Kahn, H. M. van Praag	30
13	Serotonin receptor sensitivity in major depression 1990 ·Biological Psychiatry ·RenéS. Kahn, Scott Wetzler, Gregory M. Asnis, Demitri F. Papolos, H. M. van Praag	37
14	Psychological test characteristics of depressed and panic patients 1990 ·Psychiatry Research ·Scott Wetzler, René S. Kahn, (unknown), H. M. van Praag, Gregory M. Asnis	23
15	Hypersensitivity to m-chlorophenylpiperazine in a subject with subclinical panic attacks 1990 ·Biological Psychiatry ·Oren Kalus, RenéS. Kahn, Scott Wetzler, Gregory M. Asnis, H. M. van Praag	16
16	Effects ofm-chlorophenylpiperazine in normal subjects: a dose-response study 1990 ·Psychopharmacology ·René S. Kahn, Scott Wetzler, Gregory M. Asnis, Mitchel A. Kling, Raymond F. Suckow, H. M. van Praag	84
17	Behavioral indications for serotonin receptor hypersensitivity in panic disorder 1988 ·Psychiatry Research ·(unknown), Scott Wetzler, Herman M. van Praag, Gregory M. Asnis, Timothy J. Strauman	139
18	The relationship of the dexamethasone suppression test (1 mg and 2 mg) to basal plasma cortisol levels in endogenous depression 1987 ·Psychoneuroendocrinology ·Gregory M. Asnis, Uriel Halbreich, Neal D. Ryan, (unknown), Joaquim Puig-Antich, Beverly Nelson, (unknown), Jill Harkavy‐Friedman	35
19	Sex differences in response to psychopharmacological interventions in humans. 1984 ·PubMed ·Uriel Halbreich, Gregory M. Asnis, Sheri Goldstein, Rajan Nathan, (unknown), (unknown)	11
20	Cortisol Secretion in Relation to Age in Major Depression1 1981 ·Psychosomatic Medicine ·Gregory M. Asnis, Edward J. Sachar, Uriel Halbreich, (unknown), H Novacenko, (unknown)	124

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact